---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-003896"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:18:35.381691+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VolitionRx mid-year: Vet test in 15 countries, $23M milestones, human license target H2 2024

## Summary
- Nu.Q Vet Cancer Test now available in 15 countries via Antech, IDEXX, Fujifilm; aiming to triple 2023 test sales of 58,000.
- Received $23M in upfront and milestone payments from Heska (Antech) for veterinary test.
- Preparing data rooms for Nu.Q NETs, Nu.Q Lung, and Capture-PCR technologies; first human licensing deal targeted in H2 2024.
- Capture-PCR method for direct ctDNA detection submitted for peer review July 2024; early-stage cancer discrimination demonstrated.
- Active commercial discussions with major liquid biopsy, IVD, and oncology players.

## SEC filing metadata
- accession: 0001477932-24-003896
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224003896/0001477932-24-003896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224003896/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-003896
- JSON: https://secwatch.observer/filing/0001477932-24-003896.json
- Plain text: https://secwatch.observer/filing/0001477932-24-003896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.